US 10947254
Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
granted A61KA61K31/46A61K45/06
Quick answer
US patent 10947254 (Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 56
- CPC classes
- A61K, A61K31/46, A61K45/06, A61P, A61P1/00